| Category | Key facts | Key sources (with PMID if known; otherwise DOI/URL) | Publication year |
|---|---|---|---|
| Disease entity / synonyms | GNPTG-associated disease is **mucolipidosis type III gamma (MLIIIγ)**, an attenuated lysosomal storage disorder within the MLII/III spectrum; historical synonym **pseudo-Hurler polydystrophy** is used in MLIII literature. All pathogenic **GNPTG** variants reported in the systematic review resulted in the MLIII gamma phenotype. (pqac-00000000, pqac-00000002, pqac-00000006, pqac-00000013) | Velho et al., *Hum Mutat* 2019, DOI: https://doi.org/10.1002/humu.23748; Persichetti et al., *Hum Mutat* 2009, DOI: https://doi.org/10.1002/humu.20959; Dogterom et al., *Genet Med* 2021, DOI: https://doi.org/10.1038/s41436-021-01244-4 | 2009, 2019, 2021 |
| Causal gene | Causal gene: **GNPTG**, encoding the soluble **γ-subunit of N-acetylglucosamine-1-phosphotransferase** (GlcNAc-1-phosphotransferase), part of the **α2β2γ2** hexameric complex. (pqac-00000000, pqac-00000001, pqac-00000006, pqac-00000007) | Velho et al., DOI: https://doi.org/10.1002/humu.23748; Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 | 2016, 2019, 2021 |
| Inheritance | **Autosomal recessive** inheritance. MLIIIγ is consistently described as the mildest/least severe GlcNAc-1-phosphotransferase–related mucolipidosis phenotype. (pqac-00000000, pqac-00000001, pqac-00000003, pqac-00000010) | Velho et al., DOI: https://doi.org/10.1002/humu.23748; Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Hong et al., DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 | 2016, 2019, 2023 |
| Key mechanism / pathophysiology | GlcNAc-1-phosphotransferase catalyzes the first step of **mannose-6-phosphate (M6P) tagging** of lysosomal hydrolases. GNPTG deficiency reduces phosphorylation of a subset of lysosomal enzymes, causing **missorting into the extracellular space**, lysosomal enzyme shortage within lysosomes, and accumulation of undegraded substrates in enlarged lysosomes. (pqac-00000000, pqac-00000003, pqac-00000005, pqac-00000006, pqac-00000007) | Velho et al., DOI: https://doi.org/10.1002/humu.23748; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 | 2016, 2019, 2020, 2021 |
| Variant classes / molecular effects | Reported pathogenic GNPTG variants include **missense, nonsense, splice-site, and frameshift/microdeletion** alleles. Missense variants such as **p.G106S, p.G126S, p.C142Y** can cause **misfolding, ER retention, and aggregation**; other alleles produce aberrant splicing or nonsense-mediated decay. (pqac-00000002, pqac-00000003) | Persichetti et al., DOI: https://doi.org/10.1002/humu.20959; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993 | 2009, 2016 |
| Hallmark biochemical findings | Diagnostic hallmark: **elevated lysosomal enzyme activities in plasma/serum** due to hypersecretion, with relatively **decreased or low-normal leukocyte/fibroblast activities**; urinary **GAGs are often normal** in MLII/III while oligosaccharides may be increased. (pqac-00000001, pqac-00000003, pqac-00000007, pqac-00000008, pqac-00000009) | Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; De Geer et al., DOI: https://doi.org/10.1186/s12886-023-03136-4 | 2016, 2020, 2023 |
| Quantitative biochemical examples | In the 2023 GNPTG case with retinitis pigmentosa, plasma enzymes were markedly elevated, e.g. **β-glucuronidase 1370 µkat/L vs 42 control**, **Hexosaminidase B 5190 vs 135**, **β-galactosidase 4.2 vs 0.9**; leukocyte activities were slightly decreased or low-normal. (pqac-00000008) | De Geer et al., *BMC Ophthalmol* 2023, DOI: https://doi.org/10.1186/s12886-023-03136-4 | 2023 |
| Core clinical features | Typical MLIIIγ features include **joint stiffness/restricted mobility**, **claw-hand deformity**, **short stature**, **scoliosis**, **progressive bone/joint disease**, **hip destruction/replacement**, **carpal/tarsal tunnel syndrome**, and **valvular heart disease**; intellect is often normal or only mildly affected. (pqac-00000002, pqac-00000003, pqac-00000006, pqac-00000009, pqac-00000014) | Persichetti et al., DOI: https://doi.org/10.1002/humu.20959; van Meel & Kornfeld, DOI: https://doi.org/10.1002/humu.22993; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4; De Geer et al., DOI: https://doi.org/10.1186/s12886-023-03136-4 | 2009, 2016, 2021, 2023 |
| Tissue/anatomic emphasis | Human and mouse data support major involvement of **connective tissue, cartilage, tendon, bone, and joints**; Gnptg knockout studies link enzyme missorting to **chondroitin sulfate accumulation in chondrocytes**, altered ECM structure, and functional joint abnormalities. (pqac-00000004, pqac-00000014) | Westermann et al., *Dis Model Mech* 2020, DOI: https://doi.org/10.1242/dmm.046425 | 2020 |
| Natural history / prognosis | MLIII is later-onset and longer-surviving than MLII. Systematic review statistics: **median age at diagnosis 9.0 years** for MLIII; **median survival 62.0 years**; **median age at death 33.0 years** in reported cases. (pqac-00000006, pqac-00000013) | Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 | 2021 |
| Epidemiology | Reported combined prevalence for **MLII/III** is approximately **0.22–2.70 per 100,000 live births**; GNPTG-specific prevalence was not separately quantified in the provided evidence. (pqac-00000010) | Hong et al., DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 | 2023 |
| Recent development: multiplex DBS MS/MS assay | **2023:** multiplex **UPLC-MS/MS dried blood spot** assay measured 12 lysosomal enzymes in MLII/III and showed a characteristic pattern, supporting screening/diagnosis and potential newborn screening workflows. In DBS, **ASM, IDS, and NAGLU** were significantly elevated; in the cohort these were about **20-fold, 11-fold, and 17-fold** above newborn controls, respectively. Molecular testing is still needed to distinguish MLIIIγ from other MLII/III subtypes. (pqac-00000010, pqac-00000011) | Hong et al., *Mol Genet Metab Rep* 2023, DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 | 2023 |
| Recent development: WGS phenotype expansion | **2023:** whole genome sequencing in a 47-year-old patient with late-onset retinal disease identified compound heterozygous **GNPTG** variants **c.347_349del (p.Asn116del)** and **c.607dup (p.Gln203fs)**, leading to diagnosis of MLIIIγ. This was reported as the **first description of retinitis pigmentosa/late-onset retinal dystrophy** in GNPTG-related MLIIIγ, expanding the phenotype. (pqac-00000008, pqac-00000009) | De Geer et al., *BMC Ophthalmol* 2023, DOI: https://doi.org/10.1186/s12886-023-03136-4 | 2023 |
| Current diagnostic approach | Best-supported approach combines **clinical suspicion**, **biochemical evidence of hypersecreted lysosomal enzymes** (plasma/serum ± DBS), and **molecular confirmation by GNPTG sequencing**; biochemical testing alone cannot reliably subtype MLII vs MLIIIα/β vs MLIIIγ. (pqac-00000001, pqac-00000007, pqac-00000011) | Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; Hong et al., DOI: https://doi.org/10.1016/j.ymgmr.2023.100978 | 2016, 2020, 2023 |
| Treatment status | No curative or disease-modifying therapy was identified in the provided GNPTG-focused evidence; management remains largely **supportive/symptomatic**, and curative treatment was noted as unavailable in reviews/systematic summaries. (pqac-00000001, pqac-00000005, pqac-00000006) | Sohn, DOI: https://doi.org/10.19125/jmrd.2016.2.1.13; Khan & Tomatsu, DOI: https://doi.org/10.3390/ijms21186812; Dogterom et al., DOI: https://doi.org/10.1038/s41436-021-01244-4 | 2016, 2020, 2021 |


*Table: This table condenses the core disease-defining facts for GNPTG-associated mucolipidosis type III gamma, including mechanism, clinical and biochemical hallmarks, natural history, and the most relevant 2023 diagnostic/phenotypic updates.*